Physician profile
Eric R Hansen
NPI 1770562506
$3,926.83
in general payments reported to CMS, 2019-2025
26 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $251 · 2021: $463 · 2022: $773 · 2023: $587 · 2024: $536 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,250.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $500.14 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $328.94 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.78 | 2021-2025 | Xifaxan |
| Abbott Laboratories | $165.16 | 2022-2023 | Jeti |
| Corcept Therapeutics | $141.98 | 2019-2023 | Korlym |
| Stryker Corporation | $136.05 | 2024 | |
| Lilly USA, LLC | $131.33 | 2021-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $122.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $118.42 | 2019-2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $78.97 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.21 | 2021-2022 | |
| Abbvie INC. | $64.13 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $53.55 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $43.65 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $37.89 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $29.63 | 2023 | Rexulti |
| Smith+Nephew, INC. | $29.28 | 2025 | Collagenase Santyl |
| Ultragenyx Pharmaceutical INC. | $24.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.35 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $17.84 | 2019 | |
| Exact Sciences Corporation | $14.81 | 2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $14.72 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.35 | 2019 | |
| Allergan, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.